ERBB2 and neoplasm: In addition to HER2 overexpression, genetic mutations affecting the extracellular, transmembrane, and kinase domains of ERBB2 have been reported as alternative mechanisms of HER2 activation in various solid tumors and affect tumor biology and treatment response (5–8).